Profile
María José Alonso is a Director of Advanced In Vitro Cell Technologies SL.
She is a Professor of Biopharmaceutics and Pharmaceutical Technology at the University of Santiago de Compostela.
Dr. Alonso was a Visiting Professor at the University of Angers, France and at the Massachusetts Institute of Technology from 1991 to 1992.
Previously, she was Governor for the Controlled Release Society and President of the Spanish-Portuguese Local Chapter of the CRS.
Earlier, Dr. Alonso was a Member of the Pharmaceutical Sciences of the FIP and the Scientific Advisory Board of the APGI.
She received a PhD in Pharmacy in 1985.
Former positions of María José Alonso
| Companies | Position | End |
|---|---|---|
Advancell Advanced In Vitro Cell Technologies SL
 Advancell Advanced In Vitro Cell Technologies SL BiotechnologyHealth Technology Advancell Advanced In Vitro Cell Technologies SL is a holding company engaged in the design, development, and testing of pharmaceutical products. It focuses on indications in the areas of oncology, dermatology, and neurology. Its pipeline consists of medications for hand-food syndrome, chronic lymphocytic leukemia, multiple sclerosis, psoriasis, and myelodysplastic syndromes. These are then licensed to affiliates for manufacturing and distribution. The company was founded by Susana Castel-Gil, Senen Vilar, and Manuel Reina in 2001, and is headquartered in Barcelona, Spain. | Director/Board Member | - |
Training of María José Alonso
| University of Santiago de Compostela | Doctorate Degree |
| Université Paris 1 Panthéon-Sorbonne | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 1 |
|---|---|
Advancell Advanced In Vitro Cell Technologies SL
Advancell Advanced In Vitro Cell Technologies SL BiotechnologyHealth Technology Advancell Advanced In Vitro Cell Technologies SL is a holding company engaged in the design, development, and testing of pharmaceutical products. It focuses on indications in the areas of oncology, dermatology, and neurology. Its pipeline consists of medications for hand-food syndrome, chronic lymphocytic leukemia, multiple sclerosis, psoriasis, and myelodysplastic syndromes. These are then licensed to affiliates for manufacturing and distribution. The company was founded by Susana Castel-Gil, Senen Vilar, and Manuel Reina in 2001, and is headquartered in Barcelona, Spain. | Health Technology |
- Stock Market
- Insiders
- María José Alonso
